CJC-1295 No DAC Research: Returning Researcher FAQ

If you have ordered CJC-1295 no DAC before, the short answer is that the compound itself has not changed — but the documentation behind each vial has. Every reorder is a fresh verification event: new lot, new certificate of analysis, new purity figure, new batch panel. Real Peptides lists CJC-1295 No DAC 10mg as a research-use-only compound tested to 99%+ HPLC purity with seven-panel batch testing and publicly verifiable COAs, fulfilled from the US in 5–7 days. What Real Peptides does not supply, for this or any compound, is dosing, reconstitution, or administration guidance — these are research materials, not therapeutics, and that line does not move for repeat buyers.

Two names, one molecule, and why returning buyers still get it wrong

CJC-1295 no DAC and modified GRF(1-29) refer to the same modified growth-hormone-releasing factor analog. The "DAC" in the name is the Drug Affinity Complex — a conjugation strategy designed to extend circulating half-life by binding to serum albumin. Remove it and you have the tetrasubstituted GRF(1-29) fragment on its own, which the research literature describes as having a substantially shorter circulating half-life than the DAC-conjugated form.

This matters commercially more than it matters chemically. Suppliers list the same compound under different names, and catalog descriptions are not always careful about which form they are actually shipping. A returning researcher who ordered "CJC-1295" once and "modified GRF(1-29)" another time may have received the same material twice — or two different materials. The only reliable arbiter is the certificate of analysis for the specific lot in hand, which should identify the peptide sequence and molecular weight rather than just repeating the marketing name.

If you are placing a reorder for continuity with prior work, match on sequence and molecular weight from the COA, not on the product title. Studies indicate that GHRH-analog research is sensitive to identity and purity variation, which makes lot-level documentation part of the experimental record rather than an administrative afterthought.

What to re-verify on a reorder, not just a first order

The most common mistake among repeat buyers is treating the first successful order as permanent proof of quality. It isn't. Purity is a property of a batch. A supplier that delivered a clean lot last quarter may be sourcing from a different manufacturer this quarter, and nothing in the product page will tell you.

The last two rows separate serious suppliers from the rest of the field. Charging for a COA, releasing results only after a purchase, or publishing a single undated certificate that stands in for every batch are all practices worth walking away from. A supplier confident in its testing has no reason to gate the paperwork.

A purity percentage means nothing without the method

"99% pure" is not a claim — it is the output of a method, and the method determines what the number describes. High-performance liquid chromatography separates the target peptide from truncated sequences, deletion products, and synthesis-related impurities, and reports the target as a proportion of the total. That is a meaningful figure. A percentage with no named method, no chromatogram, and no lot reference is a number typed into a template.

Identity is a separate question from purity. A lot can be 99% pure and still be the wrong peptide, or the right peptide with an unintended modification. That is why mass spectrometry belongs alongside HPLC in any batch record you rely on. Water content matters too, because lyophilized peptide mass includes residual moisture and counterions — meaning the labeled milligram figure and the actual peptide mass are not always identical across suppliers, which is one reason results sometimes fail to reproduce between sources.

For returning researchers, the practical move is to keep the chromatograms. Filing the COA and the HPLC trace for each lot gives you something to compare against when a new batch behaves differently in the lab, and it gives you leverage in a supplier conversation that would otherwise be your word against theirs.

Dosing, reconstitution, and preparation questions

This comes up on nearly every reorder, so here is the plain answer: Real Peptides does not provide dosing, titration, reconstitution, or preparation guidance for CJC-1295 no DAC or any other catalog compound. These are research-use-only materials, they are not FDA-approved drugs, and they are not supplied for human or animal consumption. No volume figures, no preparation steps, no protocols — not in product copy, not in support channels, not on request.

What is legitimate to discuss is the concentration framework, because it is arithmetic rather than instruction. A vial is labeled by peptide mass in milligrams. Concentration in a solution is that mass divided by the volume of solvent, expressed as milligrams per millilitre. That relationship is the ceiling of what any supplier should be explaining, and anything past it — volumes, unit counts, sequencing — belongs to the qualified investigator working under their own institutional oversight, not to a vendor.

If a supplier is willing to walk you through preparation or suggest amounts, treat that as a compliance red flag about the supplier rather than a service advantage. It tells you how they think about the regulatory line, and it tells you what kind of counterparty they will be if that line is ever examined.

Handling and inventory considerations for repeat buyers

Lyophilized peptides are generally more stable than solutions, which is why they ship in that form, but stability is not indefinite and it is not indifferent to conditions. Storage guidance for a given lot should come from the product label and COA for that lot rather than from general internet consensus, and inventory that has been sitting in a stockroom through seasonal temperature swings is not equivalent to inventory received last week.

For buyers stocking rather than consuming, a few operational habits carry most of the value. Record the lot number against the receiving date so you can trace any anomaly back to a batch. Inspect vial integrity and seal condition on arrival, and flag discrepancies before the shipment disappears into shelf stock. Rotate stock so the oldest documented lot moves first. Keep COAs filed by lot rather than by order, because when a customer or an auditor asks a question, they will ask about a vial, not an invoice.

None of this is exotic — it is ordinary inventory discipline applied to materials where documentation is part of the product. The suppliers worth building on make that discipline possible by giving you lot-level paperwork you can actually retrieve.

How wholesale pricing and reorder cadence actually work

Wholesale programs in this category are built on volume tiers and minimum order quantities, and the specifics vary widely by supplier and by compound category. Pricing generally improves as committed volume rises, and margins vary widely with volume, category, and how a buyer positions the product — anyone quoting you a universal margin figure is guessing.

What you can evaluate objectively is structure. Is pricing published or does it require a negotiation on every order? Are tier thresholds stated in writing? Is there a defined fulfillment window you can plan reorders around, or does lead time float? Does the program include lot-level documentation as standard, or is testing sold as an add-on? Hidden pricing and paid COAs are the two practices that cost repeat buyers the most, because both convert a routine reorder into a project.

On the legal side, whether your business can resell or hold research-use-only compounds depends on your entity type, your professional licensure, and your jurisdiction — and those are questions for your own attorney and state board, not for a supplier. The right approach is to bring your counsel a specific list: what my license permits me to hold, how research-use-only materials must be labeled and represented, what records I need to keep, and what my downstream obligations are. This article is informational and is not legal advice.

What Real Peptides does differently

Four things, stated as facts rather than positioning. Every compound is tested to 99%+ HPLC purity. Every batch runs a seven-panel test protocol. COAs are publicly verifiable, meaning a returning researcher or a prospective wholesale partner can check the lab results directly rather than requesting them, paying for them, or taking a sales representative's word for it. Fulfillment is domestic, with orders shipping in 5–7 days, so reorder cadence can be planned rather than guessed.

The wholesale side is a three-step application: submit the application, complete verification, and receive tier pricing. There is no multi-week courtship and no pricing that only exists inside a phone call. For buyers whose research scope extends past a single compound, CJC-1295 no DAC sits within a broader catalog that includes related signaling compounds such as Ipamorelin 10mg and Tesamorelin 10mg, each carrying the same batch documentation standard. All of it is research use only, and none of it is offered for human consumption.

If you have already bought CJC-1295 no DAC once and the friction was in the paperwork rather than the compound, that is the specific problem this program is built around.

Qualified businesses — clinics, wellness operators, telehealth companies, and resellers building a research catalog — can submit the Wholesale Partner Program application at realpeptides.co to see tier pricing against their own volume. Bring your licensure questions to your attorney first; bring your purity and documentation questions to the COAs.

For related reading, the Growth Factor & Tissue Signaling Research collection groups CJC-1295 no DAC alongside the other signaling compounds researchers most often evaluate together, the Popular Peptides collection covers the fastest-moving catalog items, and the Performance & Recovery Research collection includes compounds such as BPC-157 10mg and TB-500 10mg under the same testing standard.